Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,100
Employees6,100
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,100
Employees6,100

VRTX Key Statistics

Market cap
108.15B
Market cap108.15B
Price-Earnings ratio
30.21
Price-Earnings ratio30.21
Dividend yield
Dividend yield
Average volume
1.23M
Average volume1.23M
High today
$425.86
High today$425.86
Low today
$420.60
Low today$420.60
Open price
$422.05
Open price$422.05
Volume
987.83K
Volume987.83K
52 Week high
$519.88
52 Week high$519.88
52 Week low
$362.50
52 Week low$362.50

VRTX News

Nasdaq 2h
Validea Detailed Fundamental Analysis - VRTX

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twi...

Validea Detailed Fundamental Analysis - VRTX
The Motley Fool 11h
The Best Stocks to Invest $50,000 In Right Now

There's no guarantee that any stock will deliver positive returns. But the odds look good for these three. Where should I put my money? That's the question eve...

The Best Stocks to Invest $50,000 In Right Now
Simply Wall St 2d
A Look at Vertex Pharmaceuticals Valuation Following FDA Rolling Review and Key Kidney Therapy Milestones

Vertex Pharmaceuticals (VRTX) just revealed a series of milestones for its investigational therapy, povetacicept, as it moves further into late-stage trials for...

A Look at Vertex Pharmaceuticals Valuation Following FDA Rolling Review and Key Kidney Therapy Milestones

Analyst ratings

60%

of 35 ratings
Buy
60%
Hold
34.3%
Sell
5.7%

More VRTX News

TipRanks 3d
Vertex Pharmaceuticals’ Promising Kidney Franchise: Andrew Fein’s Buy Rating on Innovative Povetacicept and Strategic Expansion

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $478.00. Elevate Your Investing Strategy:...

TipRanks 3d
Vertex Pharmaceuticals: Strong Market Position and Growth Potential Reinforce Buy Rating

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Vertex Pharmaceuticals, with a price target of $563.00. Elev...

Simply Wall St 6d
Accelerated Povetacicept Progress Could Be a Game Changer for Vertex Pharmaceuticals

Vertex Pharmaceuticals recently announced several regulatory milestones for povetacicept, including FDA Breakthrough Therapy Designation and a rolling review fo...

Accelerated Povetacicept Progress Could Be a Game Changer for Vertex Pharmaceuticals

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.